Daniel Goodman

Daniel covers a wide range of biotech inventions, including therapeutic antibodies, antisense compounds, transgenic animals and cell‑based therapies. He has a sizable European prosecution practice, and regularly advocates for clients in offensive and defensive EPO opposition proceedings. Recently, Daniel was one of a trio of Carpmaels attorneys that represented Novartis in G1/22, an Enlarged Board of Appeal referral that fundamentally changed how the EPO examines priority rights. Daniel has a particular interest in antibody-related inventions. His practice has encompassed a slew of patents in the anti‑IL12, anti-IL23, anti-CD47 and anti-CD117 fields. Daniel relishes building and defending patent portfolios that protect the innovation associated with the various stages of antibody product development. New platforms, formats, targets, leads, formulations and uses each come with their own particular considerations and challenges. More generally, Daniel enjoys collaborating with the firm’s Dispute Resolution and Transactions teams to provide clients with integrated IP advice on commercially important matters such as freedom to operate, due diligence, licensing and infringement. · Carpmaels & Ransford LLP